Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ROUYN-NORANDA, Québec, 22 oct. 2019 (GLOBE NEWSWIRE) -- Ressources Explor inc. (la « Société » ou « Explor») (Bourse de croissance TSX : EXS, OTC PK : ESXFF, Bourse de Francfort et de Berlin:...
-
ROUYN-NORANDA, Québec, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Explor Resources Inc. (“Explor” or the "Corporation") (TSX-V: EXS, OTCPK: EXSFF, FSE & BE: E1H1) announces that it has amended the...
-
OTTAWA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV-CGP) (F-GWN) (B-GWN) (OTC-CTNXF) is pleased to provide an update on its Bramaderos...
-
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Routemaster Capital Inc. (TSXV: RM) (“Routemaster” or...
-
ROUYN-NORANDA, Québec, 07 oct. 2019 (GLOBE NEWSWIRE) -- ENTREPRISES MINIÈRES GLOBEX INC. (GMX – Bourse de Toronto, G1MN – Bourses de Francfort, Stuttgart, Berlin, Munich, Tradegate, Lang &...
-
ROUYN-NORANDA, Quebec, Oct. 07, 2019 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz...
-
ROUYN-NORANDA, Québec, 03 oct. 2019 (GLOBE NEWSWIRE) -- ENTREPRISES MINIÈRES GLOBEX INC. (GMX – Bourse de Toronto, G1MN – Bourses de Francfort, Stuttgart, Berlin, Munich, Tradegate, Lang &...
-
ROUYN-NORANDA, Québec, Oct. 03, 2019 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz...
-
Basel, 30. September 2019 – Basilea Pharmaceutica AG (SIX: BSLN) berichtete heute, dass am 29. September auf der Jahrestagung der Europäischen Gesellschaft für medizinische Onkologie (ESMO) in...
-
Basel, Switzerland, September 30, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that a post-hoc analysis of efficacy data from a previously completed phase 1/2 study with its oncology...